Expressing support for the designation of September 2022 as "Sickle Cell Disease Awareness Month" in order to educate communities across the United States about sickle cell disease and the need for research, early detection methods, effective treatments, and preventative care programs with respect to complications from sickle cell disease and conditions related to sickle cell disease.

Bill: 117-hres-1330
Sponsor: full_name: Rep. Davis, Danny K. [D-IL-7]
Introduced: 2022-09-02
Policy area: Health
Latest action: action_date: 2022-09-05
text: Referred to the Subcommittee on Health.

Summaries:
action_date: 2022-09-02
action_desc: Introduced in House
text: <p>This resolution expresses support for the goals and ideals of Sickle Cell Disease Awareness Month and encourages the President to support access to innovative therapies for the disease. Sickle cell disease is an inherited blood disorder than can lead to pain, anemia, infections, and stroke.</p>

tv_txt: IV 117th CONGRESS 2d Session H. RES. 1330 IN THE HOUSE OF REPRESENTATIVES September 2, 2022 Mr. Danny K. Davis of Illinois (for himself, Mr. Burgess , Ms. Lee of California , and Mr. Owens ) submitted the following resolution; which was referred to the Committee on Energy and Commerce RESOLUTION Expressing support for the designation of September 2022 as Sickle Cell Disease Awareness Month in order to educate communities across the United States about sickle cell disease and the need for research, early detection methods, effective treatments, and preventative care programs with respect to complications from sickle cell disease and conditions related to sickle cell disease.

Whereas sickle cell disease (referred to in this preamble as SCD ) is an inherited blood disorder that is a major health problem in the United States and worldwide; Whereas SCD results from an individual having two copies of a sickle cell gene, one inherited from each biological parent; Whereas SCD results in the production of abnormally shaped red blood cells; Whereas SCD causes episodes of considerable pain in the arms, legs, chest, and abdomen of an individual, which often result in lengthy hospital stays; Whereas SCD affects an estimated 100,000 individuals in the United States; Whereas approximately 2,000 babies are born with SCD each year in the United States, with the disease occurring in approximately 1 in 365 newborn African-American infants and 1 in 16,300 newborn Hispanic-American infants, and SCD can be found in individuals of Mediterranean, Middle Eastern, Asian, and Indian origin; Whereas more than 3,000,000 individuals in the United States have a single copy of the sickle cell gene, referred to as sickle cell trait, and 1 in 13 African Americans carries the trait; Whereas sickle cell trait is found in 100,000,000 people worldwide, and affects people of African, Middle Eastern, South Asian, Hispanic, and southern European Caucasian descent; Whereas there is a 1 in 4 chance that a child born to parents who both have the sickle cell trait will have the disease; Whereas the life expectancy of an individual with SCD in the United States is often severely limited to an average of 43 years for a woman and 41 years for a man; Whereas, according to a 2018 study, the total economic burden on the United States health care system associated with SCD was $2,980,000,000 annually, of which 57 percent was attributed to hospital inpatient costs; Whereas, according to a 2022 publication, the average lifetime cost for individuals most severely impacted by SCD ranges between $4,200,000 to $6,200,000 per patient; Whereas, in 2020, the National Academies of Sciences, Engineering, and Medicine developed a comprehensive Strategic Plan and Blueprint for Action to Address Sickle Cell Disease, which cited the need for new innovative therapies as well as to address barriers that may impact delivery and access to approved treatments; Whereas there are emerging genetic therapy technologies, including gene editing, that can modify a patient’s own hematopoietic stem cells with the goal of the patient being able to generate healthy red blood cells to prevent sickle cell crisis; Whereas while hematopoietic stem cell transplantation is currently the only cure for SCD and advances in treating the associated complications of SCD have occurred, more research is needed to find widely available treatments and cures to help individuals with SCD; and Whereas September 2022 has been designated as Sickle Cell Disease Awareness Month in order to educate communities across the United States about SCD, including early detection methods, effective treatments, and preventative care programs with respect to complications from SCD and conditions related to SCD: Now, therefore, be it

That the House of Representatives— (1) supports the goals and ideals of Sickle Cell Disease Awareness Month ; (2) commits to ensuring equitable access among economic, racial, and ethnic groups to new treatments in order to improve health outcomes for those with sickle cell disease; (3) calls on the Department of Health and Human Services to create policy solutions aimed at eliminating barriers to equitable access for innovative sickle cell disease therapies, including cell, gene, and gene-editing therapies, in the Medicaid and Medicare system for patients who need them most; (4) encourages the people of the United States to hold appropriate programs, events, and activities during Sickle Cell Disease Awareness Month to raise public awareness of— (A) sickle cell disease trait; (B) preventative care programs, treatments, and other patient services for those suffering from sickle cell disease; (C) complications from sickle cell disease; and (D) conditions related to sickle cell disease; (5) encourages the President of the United States to form a Sickle Cell Disease Interagency Cabinet, which would be convened by the White House, to begin working toward policies that will support equitable and appropriate access to innovative sickle cell disease therapies, by bringing together departments and agencies across the Federal Government to address sickle cell disease on multiple fronts, including— (A) the Department of Health and Human Services; (B) the Department of Veterans Affairs; (C) the National Institutes of Health; (D) the Food and Drug Administration; and (E) the Centers for Medicare & Medicaid Services; and (6) urges that the options to be considered by the Sickle Cell Disease Interagency Cabinet not only address access to potential future curative treatments, but also address the bias that those with sickle cell disease continue to face within the United States health care system.